Living Cell Technologies Limited
Algorae Pharmaceuticals Limited, a pharmaceutical development company, engages in the research and development of living cells technologies primarily in New Zealand. The company's product pipeline includes AI-116, a novel combination drug candidate made up of donepezil and cannabidiol for the treatment of dementia, including Alzheimer's disease; AI-168, a novel combination drug candidate made up … Read more
Living Cell Technologies Limited - Asset Resilience Ratio
Living Cell Technologies Limited (LVCLF) has an Asset Resilience Ratio of 77.13% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how Living Cell Technologies Limited's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Living Cell Technologies Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.85 Million | 77.13% |
| Total Liquid Assets | $1.85 Million | 77.13% |
Asset Resilience Insights
- Very High Liquidity: Living Cell Technologies Limited maintains exceptional liquid asset reserves at 77.13% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Living Cell Technologies Limited Industry Peers by Asset Resilience Ratio
Compare Living Cell Technologies Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Living Cell Technologies Limited (2016–2025)
The table below shows the annual Asset Resilience Ratio data for Living Cell Technologies Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 77.13% | $1.85 Million | $2.40 Million | +5.09pp |
| 2024-06-30 | 72.04% | $2.30 Million | $3.19 Million | +24.02pp |
| 2023-06-30 | 48.02% | $2.02 Million | $4.21 Million | +45.38pp |
| 2021-06-30 | 2.64% | $43.30K | $1.64 Million | -- |
| 2017-06-30 | 0.00% | $0.00 | $8.69 Million | -- |
| 2016-06-30 | 0.00% | $0.00 | $6.31 Million | -- |